Subsequent Entry Biologics (Biosimilars)

Learn from an expert gastroenterologist about subsequent entry biologics, also known as 'biosimilar' medication. Topics reviewed include what biosimilars are, how biosimilars differ from biologic medications, and the implications of this new treatment for individuals affected by Crohn’s or colitis.


  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest